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Abstract 
Formononetin is a bioactive non-steroidal polyphenol found in a variety of plants. In this 
study we evaluated the effects of formononetin on neuroinflammation in LPS-stimulated 
BV2 microglia. Results showed that formononetin significantly reduced the production of 
TNF-α, IL-6 and IL-1β, nitrite and PGE2, as well as protein levels of iNOS and COX-2. 
Reporter gene assays showed that formononetin produced inhibition of NF-B luciferase 
activity in HEK293 cells stimulated with TNF-α. Immunoblotting experiments revealed an 
inhibition of IKKα phosphorylation, with the resultant attenuation of phosphorylation and 
degradation of IBα following LPS stimulation. Formononetin also produced an inhibition of 
nuclear translocation and DNA binding by NF-B following LPS stimulation. RNAi 
experiments showed that transfection of BV2 microglia with ERβ siRNA resulted in the loss 
of anti-inflammatory action of formononetin. MTT assay and MAP2 immunoreactivity 
experiments showed that formononetin produced significant neuroprotective activity by 
preventing BV2 microglia conditioned media-induced toxicity to HT22 neurons. 
Investigations on the effect of formononetin on MCF7 breast cancer cells revealed that, 
while the compound significantly increased ER-luciferase activity, its effects on 
proliferation were modest. This study has established that formononetin inhibits 
neuroinflammation by targeting NF-B signalling pathway in BV2 microglia, possibly 
through mechanisms involving ERβ. Formononetin appears to modulate ERβ in MCF7 
breast cancer cells with limited proliferative effect. Formononetin could therefore serve as 
a chemical scaffold for the development of novel compounds which have selective 
neuroprotective actions in the brain. 
Keywords 
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1. Introduction 
Neuroinflammation is an important component of the pathogenesis of neurodegenerative 
diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and multiple 
sclerosis (MS). This has been demonstrated by accumulating evidence which shows that 
the β-amyloid deposits in AD patients are surrounded by reactive inflammatory mediators 
like acute phase reactant proteins, pro-inflammatory cytokines and other complement 
components 1. Similarly, the substantia nigra and striatum in the PD patients were 
observed to have high levels of proinflammatory cytokines, inducible nitric oxide synthase 
(iNOS), cyclooxygenase 2 (COX2) and activated microglia 2. 
Microglia are the resident immune cells in the central nervous system (CNS), and their 
activation has been linked to the release a host of pro-inflammatory cytokines including 
interleukin-1 beta (IL-1β), tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6), as well as 
production of nitric oxide, reactive oxygen species and other mediators associated with 
neurodegeneration 3. It is now well established that microglia-mediated 
neuroinflammation is a phenomenon that is shared by various neurodegenerative diseases 
4. 
Several reports have suggested that sex hormones might be a potential treatment for 
achieving neuroprotection in neurodegenerative disorders. The primary female hormone 
estrogen, and the primary male hormone testosterone have shown neuroprotective effects 
in the brain, and these have been found to be important in the prevention of AD 5. For 
example, estrogen has been shown to protect cultured neurons and neural cell lines from 
neurotoxicity induced by amyloid beta 5-8. Several studies have also shown that 
estrogen and selective etsrogen receptor modulators (SERMs) produce anti-inflammatory 
activity in activated microglia and in vivo 9-11. However, considering the potential for 
unwanted peripheral activity of estrogens and some SERMs, the discovery and 
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development of novel neuroprotective estrogen derivatives which do not impact negatively 
on peripheral tissues, is a promising future therapeutic option for the treatment of 
neurodegenerative disorders. 
Formononetin (7-hydroxy-4'-methoxyisoflavone) (Figure 1) is a plant-derived non-steroidal 
isoflavone with biological activities similar to those of estrogen 12, 13. Some studies 
have shown that formononetin protects neurons from oxidative stress and toxicity induced 
by L-glutamate or amyloid beta 14, 15. The compound was also shown to inhibit the 
production of TNF-α, NO and superoxide in mesencephalic neuron-glia cultures and 
microglia-enriched cultures 16. However, little is known about effects of formononetin on 
neuroinflammation induced by LPS in pure microglia cultures. Also, there is a clear gap in 
our knowledge regarding the biochemical and molecular targets involved in the actions of 
this compound in the microglia and neurons. In this study, we explored the roles of 
microglia nuclear factor-kappa B (NF-B) signalling pathway in the anti-inflammatory 
action of this compound. We also elucidated a possible involvement of microglia ERβ in 
the inhibition of neuroinflammation by formononetin. 
2. Materials and methods 
2.1 Materials 
Formononetin was obtained from Sigma, dissolved in dimethylsulfoxide (DMSO) and 
aliquots stored at -20°C. The following reagents were used: RPMI1640 (Sigma), Fetal 
bovine serum (FBS; Sigma), sodium pyruvate (Sigma), streptomycin/penicillin (Sigma), 
Eagles Minimum Essential Medium (MEM) (Life Technologies). Lipopolysaccharide (LPS) 
derived from Salmonella enterica serotype typhimurium was purchased from Caltag 
Medsystems (UK). 
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2.2 Cell culture 
BV2 mouse microglia cell line ICLCATL03001 (Interlab Cell Line Collection Banca 
Biologica e Cell Factory, Italy) were cultured in RPMI1640 medium, supplemented with 
2 mM glutamine, 10% (FBS), penicillin (100 U/ml), and streptomycin (100 μg/ml). Cells 
were maintained at sub-confluence in a CO2 incubator at 37ºC. 
The human embryonic kidney cell line 293 (HEK293; ATCC) was grown in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% FBS and 2mM glutamine.  
HT22 mouse hippocampal neuronal cells were a kind gift from Dr Jeff Davies, and cultured 
in DMEM supplemented with 10 % FBS, 100 U/ml penicillin and 100 µg/ml streptomycin in 
a 5% CO2 incubator at 37°C. 
The human breast cancer cells MCF7 (ECACC 86012803), which express both the wild 
type and variant estrogen receptors were purchased from ECACC. The cells were grown 
in Eagele’s Modified Essential Mediaum (EMEM), containing 2 mM Glutamine, 1% Non 
Essential Amino Acids (NEAA) and 10% FBS. 
2.3 Determination of TNF-α IL-1β, IL-6, PGE2 and nitrite in culture supernatants 
BV2 cells were cultured for 48 h and incubated with or without LPS (100 ng/ml) in the 
absence or presence of formononetin (2.5, 5 and 10 µM) for 24 h. Thereafter, 
supernatants were collected and analysed for levels of TNF-α and IL-6 using mouse 
ELISA kits (R&D Systems). Levels of IL-1β in culture supernatants were measured with 
mouse IL-1β ELISA kit (Biolegend, UK). All experiments were carried out according to the 
manufacturers’ instructions. Absorbance was measured in a plate reader (Infinite F50) at a 
wavelength of 450 nm. 
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Levels of PGE2 in culture supernatants were measured using an EIA kit (Arbor assay, 
USA), according to the manufacturer’s instructions. Absorbance was measured in a plate 
reader (Infinite F50) at wavelength of 450 nm. 
Nitrite concentration in the culture medium was measured using Griess assay kit 
(Promega, UK), and the calculated concentration was taken as an indicator of NO 
production. Absorbance was read at 540 nm and calculated against a sodium nitrite 
standard curve. 
2.4 Immunoblotting 
Equal amounts of protein (20 μg) were separated on a polycryamide electrophoresis gel 
and transferred onto a polyvinylidine fluoride (PVDF) membrane. Membranes were 
incubated in blocking buffer for 1 h at room temperature, washed 3 times for 10 min each 
in Tris-buffered saline containing 0.1% Tween 20 (TBS-T), and incubated with primary 
antibodies overnight at 4C. Primary antibodies used were rabbit anti-COX-2 (Santa Cruz; 
1:500), rabbit anti-iNOS (Santa Cruz, 1:500), rabbit anti-IBα (Santa Cruz; 1:250), rabbit 
anti-phospho-IκBα (Santa Cruz, 1:250), rabbit anti-IKKα (Santa Cruz; 1:250), rabbit anti-
phospho-IKKα (Santa Cruz, 1:250), rabbit anti-phospho-p65 (Santa Cruz, 1:500), rabbit 
anti-p65 (Santa Cruz 1:500), rabbit anti-microtubule-associated protein-2 (MAP2) (Santa 
Cruz, 1:500) , rabbit anti-ERβ (Santa Cruz 1:250) and rabbit anti-actin (Sigma Aldrich, 
1:500). Primary antibodies were diluted in TBS-T and 1% bovine serum albumin (BSA). 
After extensive washing (three times for 15 min each in TBS-T), proteins were detected by 
incubation with Alexa Fluor 680 goat anti-rabbit secondary antibody (1:10000; Life 
Technologies) at room temperature for 1 h. Detection was done using a LICOR Odyssey 
Imager. All Western blot experiments were carried out at least three times. 
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2.5 Reporter gene assays 
In order to determine the effect of formononetin on NF-B mediated gene expression, a 
luciferase reporter gene assay was carried out. HEK293 cells were seeded out at a 
concentration of 4 × 105 cells/ml. Twenty-four hours later, medium was changed to 
Opti-MEM and cells transfected with a Cignal NF-B reporter (SA Biosciences), using 
TransIT-LT1 transfection reagent (Mirus Bio LLC) and incubated for a further 16 h at 37ºC 
in 5% CO2. After this period, culture media was changed to DMEM and cells incubated for 
a further 8 h. Thereafter, transfected HEK293 cells were stimulated with TNF-α (1 ng/ml) in 
the presence or absence of formononetin (2.5, 5, and 10 µM) for 6 h. NFB-mediated gene 
expression was measured with ONE-Glo luciferase assay kit (Promega, Southampton, 
UK) according to the manufacturer’s instructions using a Polarstar Optima Plate reader. 
ERβ activation in MCF7 cells was also evaluated using a reporter gene assay, following a 
similar procedure. In the case of MCF7 cells, treatment was done with formononetin (2.5-
10 µM) only.  
2.6 Electrophoretic mobility shift and DNA binding assays 
Electrophoretic mobility shift assay (EMSA) was used to investigate the effects of 
formononetin on LPS-induced DNA binding by NF-B. BV2 microglia were treated with 
2.5, 5 and 10 μM formononetin 30 min prior to stimulation with LPS (100 ng/ml). After 1 h 
nuclear extracts were prepared. NF-B oligonucleotides end-labeled with IRDye 700 
provided (LI-COR Biosciences) were used for binding reactions, according to the 
manufacturer’s instructions. 
An ELISA-based DNA binding assay (EMSA) was also used to investigate the effects of 
formononetin on DNA binding of NF-κB. BV2 microglia were treated with formononetin 
(2.5–10 μM). Thirty minutes later, cells were stimulated with LPS (100 ng/ml) for a further 
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1 h. Thereafter, DNA binding assays were carried on nuclear extracts using the TransAM 
NF-κB transcription factor EMSA kit containing immobilised NF-κB consensus site (5′ 
GGGACTTTCC-3′) (Activ Motif, Belgium) according the manufacturer's instructions and 
described previously 17. 
2.7 Immunofluorescence microscopy 
Treated cells were fixed with ice-cold 100% methanol at −20°C for 15 min and washed 
3 times with phosphate buffered saline (PBS) for 5 min. Non-specific binding was blocked 
by incubating cells in 5% BSA blocking solution (containing 10% horse serum in 1X TBS-
T) for 60 min at room temperature. This was followed by washing with PBS. Thereafter, 
the cells were incubated with the following primary antibodies overnight at 4°C: rabbit anti-
NF-B p65 (Santa Cruz; 1:100), rabbit anti-ERα (Abcam; 1:100), rabbit anti-ERβ (Santa 
Cruz; 1:100) and rabbit anti-MAP2 (Santa Cruz; 1:100). Following overnight incubation, 
cells were washed thrice with PBS and incubated for 2 h in the dark with Alexa Fluor 488-
conjugated donkey anti-rabbit IgG secondary antibody (Life Technologies; 1:500). 
Thereafter, cells were washed with PBS and counterstained with DAPI for 5 min. After 
rinsing cells with PBS, excess buffer was removed and gold antifade reagent (Invitrogen) 
was added. All staining procedures were performed at room temperature. Fluorescence 
images were obtained using EVOS® FLoid® cell imaging station. 
2.8 RNA interference 
Small interfering RNAs (siRNAs) targeting ERβ (Santa Cruz Biotechnology) were used to 
silence ERβ gene. BV2 cells were cultured until they were 70% confluent. Transfections of 
ERβ and control siRNA duplexes onto the cells were carried out as earlier described 18. 
Following transfection, cells were treated with formononetin (10 μM), followed by LPS 
(100 ng/ml). Levels of nitrite, PGE2 and TNF-α were measured in culture supernatants of 
both ERβ-silenced and control cells. Also, protein levels of phospho-p65 were measured 
9 
 
using immunofluorescence.Transfection efficiency was determined by preparing whole cell 
extract from both control siRNA and ERβ-siRNA-transfected BV2 cells, and western blot 
carried out to measure levels of ERβ protein.  
2.9 MTT assay for cell viability 
BV2 cells were cultured for 48 h and incubated with or without LPS (100 ng/ml) in the 
absence or presence of formononetin (2.5, 5 and 10 µM) for 24 h. 3-(4, 5-dimethylthiazol-
2-yl)-2,5- diphenyl tetrazolium bromide (MTT) solution (5 mg/ml; Sigma) was then added to 
each well. The plate was then incubated for 4 h at 37ºC, followed by removal of 190 µl of 
medium from each well. Therefater, 190 µl of DMSO solution was added to each well. 
After the formazan crystals had dissolved, absorbance was read at 540 nm with Tecan 
F50 microplate reader. 
2.10 BV2 microglia conditioned media-induced neurotoxicity 
BV2 microglial cells were pre-treated with formononetin (2.5–10 µM) prior to stimulation 
with LPS (1 µg/ml). After 24 h incubation, supernatants were collected and centrifugated 
(conditioned media). Cultured HT22 hippocampal neuronal cells were then incubated with 
BV2 microglia conditoned media for 24 h. At the end of the experiment, 190 µl MTT 
solution (5 mg/ml) was added to each well containing HT22 neurons and incubated at 
37ºC for 4 h. Then, 190 µl of the medium was removed and 150 µl of DMSO solution was 
added to wells to dissolve the formazan crystals. Thorough mixing of the preparation was 
facilitated by shaking the plate for a few seconds before absorbance was read at 540 nm 
with a plate reader. 
2.11 Neuron-BV2 microglia transwell cultures 
Neuron-BV2 microglia transwell cultures were also used to investigate microglia-mediated 
neurotoxicity. HT22 mouse hippocampal neurons were seeded out in 96-well dishes. BV2 
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microglia were seeded out in transwell chambers (0.4 µm; Corning). Inserts were placed 
on top of the wells containing HT22 neuronal culture. The microglia layer was then treated 
with formononetin (2.5, 5 and 10 µM), followed by LPS (1 µg/ml) for 24 h. Neuronal 
viability was determined using MTT assay. 
2.12 E screen assay for proliferation of MCF7 human breast cancer cells 
The E screen assay was used to determine the estrogenic effect of formononetin by 
measuring its ability to induce proliferation of MCF7 human breast cancer cells in an 
estrogen-free medium. MCF7 cells are known to respond to estrogenic compounds which 
act by binding to estrogen receptor, resulting in cell proliferation. This experiment was 
carried out as described by Resende et al. (2013), with some modifications 19. Briefly, 
MCF7 cells were seeded in 24-well plates. After 24 h, cells were washed with PBS, and 
Serum Replacement 2 was added to the cells. Cells were then treated with formononetin 
(2.5, 5 and 10 µM) or 17β-estradiol and incubated for 6 days. Thereafter, Serum 
Replacement 2 was removed from the cells, followed by sulforhodamine B assay. 
Proliferative effect was calculated as: 
Proliferative Effect of Treatment/17β-estradiol = Absorbance of treated cells/Absorbance of 
untreated control.  
Relative Proliferative Effect (%) = [Proliferative Effect of Treatment / Proliferative Effect of 
17β-estradiol] × 100 
2.13 Statistical Analysis 
All experiments were performed at least three times and in triplicates unless otherwise 
stated. Data are expressed as mean ± standard deviation (SD). Statistical analysis was 
performed using one way ANOVA with post-hoc Tukey test (multiple comparisons). 
11 
 
3. Results 
3.1 Formononetin did not effect BV2 cell viability  
In order to determine whether formononetin affected the viability of BV2 cells, an MTT 
assay was carried out after incubating the cells with the compound for 24 h. Results 
showed that there was no significant difference in the viability of cells treated with 
formononetin (2.5, 5 and10 μM) when compared with control (untreated) cells (Figure 2). 
3.2 Formononetin reduced TNF-α, IL-1β and IL-6 production in LPS-activated BV2 
microglia 
The release of pro-inflammatory cytokines is now known to be a major process in 
neuroinflammation. Consequently, we were interested to know if pre-treatment with 
formononetin would suppress the release of TNF-α, IL-1β and IL-6 in LPS-activated BV2 
microglia. Stimulation of the cells with LPS (100 ng/ml) resulted in a significant increase in 
the secretion of TNF-α in comparison with unstimulated cells (Figure 3a). Similar results 
were obtained following measurements of IL-6 levels in culture supernatants (Figure 3b). 
On pre-treating the cells with formononetin (2.5, 5 and 10 µM), there was a significant 
reduction in TNF-α production, in comparison with LPS control (Figure 3a). Similarly, levels 
of IL-6 secreted into culture supernatants was significantly (p<0.05) reduced by 5 and 
10 µM formononetin (Figure 3b). Similar results were obtained following analysis of 
supernatants for levels of IL-1β (Figure 3c). 
3.3 Formononetin inhibited nitrite production through suppression of iNOS 
protein in LPS-activated BV2 microglia 
We evaluated the effect of formononetin on nitrite production in LPS-stimulated microglia, 
and found that the compound  dose-dependently inhibited nitrite production (Figure 4a). 
Further investigation using western blotting showed that formononetin (2.5, 5 and 10 µM) 
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produced significant (p<0.001) suppression of iNOS protein levels (Figure 4b). These 
results suggest that formononetin suppressed NO production in LPS-activated BV2 
microglia through inhibition of iNOS protein expression. 
3.4 Formononetin prevented COX-2-mediated PGE2 production in LPS-activated 
BV2 microglia  
As shown in Figure 5a, LPS-stimulated BV2 cells produced detectable levels of PGE2 
compared with unstimulated cells. Formononetin (2.5, 5 and10 μM) significantly reduced 
PGE2 production in a concentration-dependent manner. Also results in Figure 5b show 
marked increase in COX-2 protein in LPS stimulated cells. However, pre-treatment with 
formononetin (2.5, 5 and 10 μM) significantly attenuated LPS-induced COX-2 protein 
expression. 
3.5 Formononetin inhibits neuroinflammation by targeting NF-B signalling 
pathway 
NF-B is a transcription factor that plays important roles in the immune system. NF-B 
regulates the expression of cytokines, (COX-2). To determine whether formononetin 
shows any general effect on NF-B-mediated gene transcription, a luciferase reporter 
gene assay was used. HEK293 cells were transfected with a vector containing NF-B 
regulated luciferase reporter construct, and the experiment revealed that formononetin 
(2.5, 5 and 10 μM) significantly (p<0.001) inhibited NF-B regulated luciferase reporter 
gene expression following stimulation with TNF-α (1 ng/ml) (Figure 6a). 
We next investigated the effects of formononetin on NF-B signalling activated following 
treatment of BV2 microglia with LPS (100 ng/ml). One of the early steps in NF-B 
signalling is the phosphorylation of IKKα. Results in Figure 6b shows the expected 
increase in phosphorylation of following stimulation with LPS, which was reduced by pre-
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treatment with formononetin 30 min prior to LPS stimulation (Figure 6b). Following IKK 
activation, the kinase phosphorylates IB, followed by its subsequent proteasomal 
degradation. We were able to show that formononetin pre-treatment prevented both 
phosphorylation and degradation of IB protein as a result of stimulation with LPS 
(100 ng/ml) (Figure 6c). The next step involved using western blotting and 
immunofluorescence to demonstrate an inhibition of LPS-induced phosphorylation 
(Figure 6d) and nuclear localisation (Figure 6e) of NF-B p65 sub-unit with formononetin 
(2.5-10 µM) pre-treatment. 
Encouraged by the results showing that formononetin inhibits neuroinflammation by 
targeting NF-B activation pathway in BV2 microglia, we were interested in determining 
the effects of this compound on DNA binding by NF-B. Two methods were used to 
evaluate this activity. Results of EMSA experiments in Figure 6f clearly shows that 
stimulation with LPS resulted in the binding of NF-B in the nuclear extract to its 
consensus site on the DNA. This phenomenon was clearly reduced in BV2 cells that were 
pre-treated with formononetin. These observations were further confirmed using 
quantitative NF-B DNA binding assays, which show a similar trend of LPS-induced DNA 
binding of NF-B (Figure 6g). However, pre-treatment with formononetin (2.5-10 µM) 
resulted in inhibition of DNA binding by NF-B. All these results appear to suggest that 
formononetin interferes with multiple steps in the signalling pathway involving NF-B in 
BV2 microglia. 
3.6 Formononetin increases levels of ERβ protein in BV2 microglia 
Experiments were conducted to determine whether formononetin would increase the 
expression of ER protein in BV2 microglia. Initial immunofluorescence experiments 
revealed that ERα protein was undetectable in BV2 microglia, while appreciable levels of 
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basal ERβ were detected in these cells (Figures 7a). Encouraged by this outcome, we 
evaluated the effect of formononetin treatment on protein levels of ERβ in BV2 microglia. 
Results of immunoblotting experiments revealed that at 2.5 µM, there was no significant 
increase in the levels of ERβ. On increasing the concentrations of formononetin to 5 and 
10 µM, there was a significant (p<0.01) increase in ERβ expression (~1.5 and ~1.75-fold 
increase, respectively) (Figure 7b). Interestingly, immunofluorescence results showed an 
increase in immunostaining for ERβ at all the concentrations tested (Figure 7c), an 
outcome that may be as a result of differences in sensitivities of the two methods. 
3.7 Inhibition of neuroinflammation by formononetin was reversed by knockdown 
of ERβ in LPS-activated BV2 microglia 
In order to understand any possible roles played by activation of ERβ in the 
anti-inflammatory effects of formononetin, we investigated the effects of the compound on 
the production of inflammatory mediators in ERβ siRNA-transfected BV2 microglia. Results 
showed that in control siRNA-tranfected cells which were treated with formononetin 
(10 µM) prior to stimulation with LPS (100 ng/ml), there was a significant (p<0.05) 
reduction in the production of nitrite, PGE2 and TNF-α, in comparison with LPS control 
(Figures 8a-c). These anti-inflammatory effects were significantly (p<0.01) reversed in ERβ 
siRNA-transfected cells, in comparison with control-siRNA cells (Figures 8a-c).  
Similarly, Figure 8d shows that LPS stimulation resulted in nuclear translocation of the 
NF-B p65 subunit in control siRNA transfected BV2 cells, in comparison with 
unstimulated cells. This process was blocked in the presence of formononetin (10 µM). 
However, when cells were transfected with ERβ siRNA, formononetin lost its ability to 
prevent LPS-induced nuclear translocation of NF-B p65 subunit. Transfection efficiency 
using western blotting revealed presence of ERβ protein in control siRNA transfected cells, 
while there was a downregulation of the protein in ERβ knockdown cells (Figure 8e). 
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3.8 Formononetin protects HT22 neurons from BV2 microglia conditioned media-
mediated toxicity 
Our results showing that formononetin inhibits neuroinflammation encouraged us to ask 
whether this compound could prevent neuroinflammation-mediated neurotoxicity. BV2 
microglia were pre-treated with formononetin and then stimulated with LPS for 24 h. 
Cultured HT22 cells were then exposed to conditioned media from the stimulated BV2 
microglia for a further 24 h. MTT assay results showed a significant (p<0.01) reduction in 
the viability of HT22 neurons following addition of conditioned media from LPS-stimulated 
BV2 cells (Figure 9a). However, neuronal viability was significantly (p<0.05) increased 
following exposure to conditioned media from BV2 cells that were pre-treated with 
formononetin (2.5-10 µM) prior to LPS stimulation, in comparison with LPS alone.  
The microtubule associated protein 2 (MAP2) is a protein that functions to maintain 
neuronal morphology and used as a marker of neuronal integrity. Western blotting and 
immunostaining for MAP2 protein confirmed an increase in MAP2 protein in HT22 neurons 
as a result of pre-treating BV2 microglia with formononetin (2.5-10 µM) prior to exposing 
the neurons to microglia conditioned media (Figures 9b and 9c). 
Further experiments to evaluate the neuroprotective effect of formononetin using BV2 
microglia/HT22 neuron transwell co-culture revealed a similar trend as the conditioned 
media-induced neurotoxicity. Figure 9d shows a reduction in viability of HT22 neurons that 
were co-cultured with BV2 microglia stimulated with LPS, in comparison with neurons co-
cultured with unstimulated BV2 cells. However, pre-treatment of BV2 microglia with 
formononetin (2.5-10 µM) prior to LPS stimulation resulted in improved viability of 
respective adjacent neurons.  
3.9 Effects of formononetin on MCF7 human breast cancer cells 
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Firstly, we wanted to determine the effect of formononetin on the transcriptional activity of 
estrogen receptors in MCF7 breast cancer cells. Our results revealed that treatment of 
these cells with 17β-oestradiol (10 nM) resulted in significant (p<0.01) increase in estrogen 
response elements (ERE) luciferase activity (Figure 10a). Similarly, on treating cells with 
formononetin (2.5-10 µM), there was a significant (p<0.05) and concentration-dependent 
increase in luciferase activity. Our results also revealed that treatment with 17-β-oestradiol 
(10 nM) resulted in significant (p<0.001) proliferation of MCF7 cells (Figure 10b and 10c). 
Interestingly, there was no difference in proliferation between control cells and cells treated 
with formononetin (2.5 and 5 µM). On increasing the concentration of the compound to 
10 µM, there was a slight but insignificant increase in the proliferation of MCF7 cells 
(Figures 10b and c). 
4. Discussion 
Recent studies have clearly shown that estrogen-like compounds which inhibit 
neuroinflammation provide therapeutic opportunities in neurodegenerative disorders like 
AD. In this study we investigated inhibition of neuroinflammation by formononetin in BV2 
microglia stimulated with LPS, and found that the compound suppressed production of the 
pro-inflammatory cytokines TNF-α, IL-6 and IL-1β from the cells. Our results also 
demonstrated an attenuation of iNOS-mediated NO and COX-2-mediated PGE2 
production from LPS-activated BV2 microglia. These results suggest that formononetin 
prevents neuroinflammation resulting from stimulating BV2 microglia with LPS. We also 
showed that pre-treatment of BV2 microglia with formononetin prevented microglia 
conditioned medium- and BV2 microglia/neuron transwell co-culture-induced neurotoxicity 
in HT22 hippocampal neurons, further suggesting that the anti-inflammatory activity of this 
compound could be useful in neuroinflammation-mediated neurodegeneration. 
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Neuroinflammation has been strongly linked to the aetiopathogenesis of 
neurodegenerative disorders such as AD 20 and PD 21. While it is widely recognised 
that diverse neuroinflammatory signals contribute to the pathogenesis of these conditions, 
our results seem to suggest that the anti-inflammatory action of formononetin could be 
exploited in AD and PD therapeutics. Previously, formononetin isolated from various 
natural sources has been reported to have inhibitory effects on LPS-stimulated nitric oxide 
release in LPS-stimulated RAW264.7 cells 22 as well as pro-inflammatory cytokine 
production in bone marrow-derived dendritic cells 23. Furthermore, formononetin was 
reported to inhibit both TNF-α and NO production from neuron-glia cultures and microglia-
enriched cultures 16. Our results have confirmed these results on anti-inflammatory 
effects of formononetin in peripheral inflammatory cells, and showed for the first time that 
the compound blocks the production of a variety of pro-inflammatory mediators and 
proteins in pure microglia culture stimulated with LPS. 
It is now widely accepted that the transcription factor, NF-B plays a significant role in 
neuroinflammation and neurodegeneration. Furthermore accumulating evidence suggests 
that disease modifying drugs for neurodegenerative disorders which inhibit 
neuroinflammation act by inhibiting NF-κB activation either directly or indirectly 24. 
Consequently, the molecular mechanism of anti-neuroinflammatory action of formononetin 
in BV2 microglia was elucidated by investigating its effects on important steps in the 
NF-B signalling pathway. Firstly, using HEK293 cells transfected with a plasmid construct 
bearing a luciferase reporter gene under the control of NF-B, we showed that 
formononetin inhibited the transcriptional activity of NF-B in general. It was further 
established that in LPS-stimulated BV2 microglia, formononetin inhibited ciritical steps 
involving IKK-mediated phosphorylation and degradation of IB, nuclear translocation as 
well as DNA binding of NF-B. 
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Several studies have reported NF-B inhibitory activity of formononetin in various cellular 
models. Inhbition of IL-1β-induced NO/iNOS and apoptosis in INS1 panceratic beta cells 
by formononetin has been attributed to its ability to inhibit the activation of NF-B 25. 
Inhibition of H2O2-induced apoptosis in retinal ganglion cells by formononetin has also 
been linked to inhibition of NF-B activation 26. Furthermore formononetin was reported 
to inhibit NF-B signalling pathway in bone-marrow-derived macrophages stimulated with 
receptor activator of NF-B ligand (RANKL) 27. Biochanin A is a closely related 
compound to formononetin which has been reported to inhibit neuroinflammation in the 
microglia 28-30. However, to our knowledge this is the first report showing inhibition of 
neuroinflammation through NF-B signalling pathway in LPS-activated microglia by 
formononetin, and provides further evidence on the anti-neuroinflammatory potential of the 
compound. 
Several studies have suggested anti-neuroinflammatory actions of estrogens in animal 
models and in vitro. It has also been suggested that this action may account for their 
neuroprotective activity in the brain. However, the risk of tumours associated with estrogen 
has led to investigations of neuroprotective selective estrogen receptor modulators 
(SERMs) which may act as selecetive estrogen enzyme modulators (SEEMs). Considering 
our results showing inhibition of neuroinflammation by this compound, we were interested 
in establishing the role of interaction with estrogen receptors in its anti-inflammatory 
activity in the microglia.  
In order to establish whether formononetin has an effect on protein levels of estrogen 
receptors in the microglia, firstly we were interested in confirming the subtype of esterogen 
receptors that are expressed in these cells. Interestingly, our results showed that BV2 
microglia express ERβ estrogen receptor rather than ERα. This is consistent with earlier 
reports showing that estrogen reduces production of pro-inflammatory mediators from BV2 
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microglia through interactions with ERβ 31, 32. We further showed that treatment of BV2 
microglia with formononetin resulted in an increase in the levels of ERβ protein, further 
suggesting that the compound possibly modulates the activity of the estrogen enzyme in 
the microglia.  
The results showing that formononetin increased the level of ERβ in the microglia are quite 
intriguing. We therefore hypothesised that this action of the compound contribute to its 
anti-inflammatory activity in the microglia. We tested this hypothesis by investigating anti-
inflammatory activity of formononetin in ERβ knockdown BV2 cells. We were able to show 
that silencing ERβ resulted in the loss of anti-inflammatory activity of formononetin in BV2 
microglia. We further showed that silencing ERβ resulted in the loss of the ability to 
prevent translocation of p65 sub-unit. These results clearly suggest a significant 
contribution by ERβ in NF-B-mediated inhibition of neuroinflammation by formononetin, 
an outcome that is being reported for the first time.  
Studies have suggested that oestrognic compounds may be interfering with 
NF-B-mediated neuroinflammation by targeting translocation of NF-B. For example, 
oestradiol has been a targets. Future studies will need to confirm this hypothesis.  
A major limitation with estrogenic compounds is their tendency to induce proliferation of 
certain cancer cells, especially breast cancer cells. In fact some studies have aimed to 
establish the potential effects of formononetin on breast cancer cells. A study by Wang et 
al. reported estrogenic receptor mediated proliferation of mammary glands in mice treated 
with formononetin 36. Similar observations were made in vitro in MCF7 breast cancer 
cells by Ji et al. 37. However, recent studies have reported that formononetin showed 
activities which were consistent with anticancer activity in MCF7 cells 38-40. 
Interestingly, our results showed that formononetin increased transcriptional activity of 
estrogen receptors in MCF7 cells. However, its effect on the proliferation of these cells 
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was found to be insignificant. On the other hand, significant transcriptional activity and 
proliferative effects were shown by 17β-oestradiol treatment. 
This study has established that formononetin inhibits neuroinflammation by targeting 
NF-B signalling pathway in BV2 microglia. Formononetin interacts with ERβ in the 
microglia, an action that possibly contributes to its anti-inflammatory activity. We further 
demonstrated that this compound interacts with estrogen receptors in MCF7 breast cancer 
cells with limited proliferative effect. While it is not clear whether this compound has a 
cancer risk when used in neurodegenerative disorders, it serves as an excellent chemical 
scaffold for the development of novel compounds which have selective actions in the 
brain. 
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Figure Legends 
Figure 1  
Chemical structure of formononetin. 
Figure 2 
Pre-treatment with formononetin (2.5, 5 and10 μM) did not affect the viability of BV2 
microglia stimulated with LPS (100 ng/ml) for 24 h. All values are expressed as mean ± 
SD for 3 independent experiments. 
Figure 3 
Formononetin reduced TNF-α (a), IL-6 (b) and IL-1β (c) production in LPS-activated 
BV2 microglia. Cells were stimulated with LPS (100 ng/ml) in the presence or absence 
of formononetin (2.5, 5 and 10 μM) for 24 h. At the end of the incubation period, 
supernatants were collected and pro-inflammatory cytokines analysed with ELISA. 
Data are expressed as mean ± SD for 3 independent experiments. Statistical analysis 
was performed using one way ANOVA with post-hoc Tukey test (multiple 
comparisons). **p<0.01, ***p<0.001; in comparison with LPS control. 
Figure 4 
Formononetin produced iNOS-mediated reduction in NO production in BV2 cells 
stimulated with LPS. BV2 cells were stimulated with LPS (100 ng/ml) in the presence or 
absence of formononetin (2.5, 5 and 10 μM) for 24 h. Culture supernatants were 
collected to measure levels of nitrite using Griess assay (a) and iNOS protein using 
immunoblotting (b). Data are expressed as mean ± SD for 3 independent experiments. 
Statistical analysis was performed using one way ANOVA with posthoc Tukey test 
(multiple comparisons). ***p<0.001; in comparison with LPS control. 
Figure 5 
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Formononetin produced COX-2-mediated reduction in PGE2 production in BV2 cells 
stimulated with LPS. BV2 cells were stimulated with LPS (100 ng/ml) in the presence or 
absence of formononetin (2.5, 5 and10 μM) for 24 h. Culture supernatants were 
collected to measure levels of PGE2 using EIA (a) and COX-2 protein using 
immunoblotting (b). Data are expressed as mean ± SD for 3 independent experiments. 
Statistical analysis was performed using one way ANOVA with posthoc Tukey test 
(multiple comparisons). *p<0.05, ***p<0.001; in comparison with LPS control. (ns: not 
significant). 
Figure 6 
Inhibition of TNF-α-induced NF-B-dependent luciferase activity in HEK293 cells by 
formononetin (a). Formononetin suppressed IKK-mediated phosphorylation and 
degradation of IB. BV2 microglia were stimulated with LPS (100 ng/ml) in the 
presence or absence of formononetin (2.5, 5 and10 μM) for 30 min. Immunoblotting 
was carried out using anti-IKKα, anti-phospho-IBα and anti-IBα antibodies (b,c). 
Formononetin interfered with nuclear translocation of NF-B p65 subunit through 
inhibition of p65 phosphorylation as determined by immunoblotting (d) and nuclear 
accumulation of p65 evaluated with immunofluorescence (e). Binding of NF-B to the 
DNA was suppressed by formononetin in EMSA (f) and DNA binding assays (g). All 
values are expressed as mean±SD for 3 independent experiments. Data were 
analysed using one-way ANOVA for multiple comparison with post-hoc Tukey 
test.**p<0.01, ***p<0.001; in comparison with TNF-α or LPS control. 
Figure 7 
Cultured BV2 microglia express ERβ, but not ERα protein, as determined by 
immunofluorescence (a). Formononetin treatment resulted in upregulation of ERβ 
protein in BV2 microglia (b, c). All values are expressed as mean±SD for 3 
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independent experiments. Data were analysed using one-way ANOVA for multiple 
comparison with post-hoc Tukey test. **p<0.01, ***p<0.001; in comparison with LPS 
control. (ns: not significant). 
Figure 8 
Inhibition of neuroinflammation by formononetin was abolished with ERβ siRNA 
transfection in LPS-activated BV2 microglia. Control siRNA- and ERβ siRNA-
transfected BV2 cells were treated with formononetin (10 µM) for 30 min prior to 
stimulation with LPS (100 ng/ml) for 24 h. Supernatants were collected to measure 
levels of nitrite (a), PGE2 (b) and TNF-α (c). Immunofluorescence detection for p65 (d). 
Immunoblotting for ERβ was carried out to evaluate transfection efficiency (e). All 
values are expressed as mean±SD for 3 independent experiments. Data were 
analysed using one-way ANOVA for multiple comparison with post-hoc Tukey test. 
**p<0.01, ***p<0.001; comparing control siRNA- and ERβ siRNA-transfected BV2 cells. 
Figure 9 
Neuroprotection against microglia conditioned media-induced toxicity to HT22 cells by 
formononetin. BV2 microglia were treated with formononetin (2.5-10 µM) followed by 
stimulation with LPS (1 µg/ml) for 24 h. Cultured HT22 mouse hippocampal neurons 
were then exposed to conditioned media and viability determined using MTT assay (a) 
and MAP2 immunodetection (b, c). MTT viability assay showing neuroprotective effect 
of formononetin in BV2 microglia/HT22 neuron transwell co-culture (d). All values are 
expressed as mean±SD for 3 independent experiments. Data were analysed using 
one-way ANOVA for multiple comparison with post-hoc Tukey test. **p<0.01, 
***p<0.001; in comparison with conditioned media from LPS-stimulated BV2 microglia 
only. (ns: not significant). 
Figure 10 
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Effect of formononetin in MCF7 breast cancer cells. Formononetin (2.5-10 µM) and 
17-β-oestradiol significantly increased ER-mediated luciferase activity in MCF7 cells 
(a). 17-β-oestradiol, but not formononetin produced significant proleiferation of MCF7 
cells as determined using the E screen assay (b, c).  
Proliferative Effect of Treatment/17β-estradiol = Absorbance of treated 
cells/Absorbance of untreated control.  
Relative Proliferative Effect (%) = [Proliferative Effect of Treatment / Proliferative 
Effect of 17β-estradiol] × 100 
All values are expressed as mean±SD for 3 independent experiments. Data were 
analysed using one-way ANOVA for multiple comparison with post-hoc Tukey test. 
*p<0.05, **p<0.01, ***p<0.001; in comparison with control treatment. (ns: not 
significant). 
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